The WACC of Genetic Signatures Ltd (GSS.AX) is 7.9%.
Range | Selected | |
Cost of equity | 6.3% - 9.5% | 7.9% |
Tax rate | 30.0% - 30.0% | 30% |
Cost of debt | 4.6% - 4.6% | 4.6% |
WACC | 6.3% - 9.4% | 7.9% |
Category | Low | High |
Long-term bond rate | 4.0% | 4.5% |
Equity market risk premium | 5.1% | 6.1% |
Adjusted beta | 0.44 | 0.73 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.3% | 9.5% |
Tax rate | 30.0% | 30.0% |
Debt/Equity ratio | 0.01 | 0.01 |
Cost of debt | 4.6% | 4.6% |
After-tax WACC | 6.3% | 9.4% |
Selected WACC | 7.9% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
GSS.AX | Genetic Signatures Ltd | 0.01 | 0.95 | 0.94 |
039860.KQ | NanoEnTek Inc | 0 | 0.94 | 0.94 |
043090.KQ | Cube&Company Co Ltd | 2.66 | -0.63 | -0.22 |
206650.KQ | EuBiologics Co Ltd | 0.03 | 0.16 | 0.15 |
220100.KQ | Futurechem Co Ltd | 0.03 | 0.38 | 0.38 |
BPH.AX | BPH Energy Ltd | 0.01 | 0.18 | 0.18 |
CTE.AX | Cryosite Ltd | 0.06 | -0.44 | -0.42 |
MEM.AX | Memphasys Ltd | 0.4 | -0.11 | -0.09 |
PAL.AX | Palla Pharma Ltd | 0.39 | 1.18 | 0.93 |
SUVEN.NS | Suven Life Sciences Ltd | 0 | 1.63 | 1.63 |
Low | High | |
Unlevered beta | 0.17 | 0.6 |
Relevered beta | 0.16 | 0.6 |
Adjusted relevered beta | 0.44 | 0.73 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for GSS.AX:
cost_of_equity (7.90%) = risk_free_rate (4.25%) + equity_risk_premium (5.60%) * adjusted_beta (0.44) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.